Every retatrutide FDA warning letter, regulator alert, seizure, lawsuit and lab test we could check, newest first, each linked to its source and date-stamped.
Retatrutide safety and regulatory log
Regulator warnings, seizures, court filings, harm reports and lab tests, each linked to its source. Last checked .
Showing 36 of 36 entries, newest first
WarningAustralia
Sport Integrity Australia
Sport Integrity Australia's retatrutide page (as archived on Oct 22, 2026) says retatrutide is not on the 2026 Prohibited List, but counterfeit products may be contaminated with banned substances that could cause an anti-doping rule violation.
What it means: For tested athletes the risk is what else is in the vial. The page has no publication date, so we list it at the date we could confirm it.
CBS News reported that it bought products sold as retatrutide and had University of Iowa researchers test them. Two online samples matched a basic retatrutide standard; a $90 vial from a bodega held no apparent peptide, a filler (phenylacetic acid) and 13 colonies of bacteria.
What it means: One outlet's test of a few products, not a regulator survey. Even the samples that matched weren't shown to be the molecule in Lilly's trials.
MHRA and West Midlands Police seized more than 12,000 fake retatrutide and tirzepatide pens and packaging for about 30,000 more at an industrial unit in Birmingham, about £2 million of product.
What it means: The fourth large UK seizure involving retatrutide in a year. MHRA says products sold as retatrutide outside clinical trials are supplied illegally.
CBS News reported that FDA's Adverse Event Reporting System received 2 death reports after people used products sold as retatrutide: a 41-year-old woman with obesity who went into cardiac arrest (July 2026) and a 49-year-old patient (September 2026). FDA would not say whether it verified either one.
What it means: A report to FDA is a signal to investigate, not proof that the product caused the death. FDA has not published these reports itself.
CBS News reported that America's Poison Centers logged 249 retatrutide exposures in January to March 2026, 460 in April to June and 862 in the three months ending in September.
What it means: An exposure is a call about contact with a product, not a confirmed poisoning. We found no Poison Centers page with these counts. US Poison Help is 1-800-222-1222, free and confidential.
Both sides filed their jurisdiction briefs. The government argued that "Lilly cannot appeal a district court's order remanding to an agency"; Lilly said FDA's new decision confirms "that this appeal is the only proceeding that can address the issues presented here".
What it means: The court first has to decide whether it can hear the appeal at all. We found no ruling as of November 1, 2026.
On remand, FDA decided again that retatrutide is not a biological product, so "an application for retatrutide would need to be submitted under section 505 of the Federal Food, Drug, and Cosmetic Act."
What it means: FDA's position is that retatrutide gets filed as a drug, not a biologic. Lilly's appeal on that question is still pending.
Singapore's Health Sciences Authority said unapproved injectable peptides such as retatrutide are marketed on social media for weight loss and muscle gain, and that it has received reports of anaphylaxis, abdominal pain, diarrhoea and vomiting after people used products bought online.
What it means: In Singapore, report suspicious sales to HSA on 6866-3485 or hsa_is@hsa.gov.sg.
The Seventh Circuit (Judges Brennan, Easterbrook and Kirsch) ordered both sides to file memos on whether it has jurisdiction to hear Lilly's appeal of a remand, due Oct 8, 2026.
What it means: A procedural order, not a ruling on whether retatrutide is a drug or a biologic.
La Capital (Mar del Plata) reported that ANMAT Disposición 6140/2026, published in the Boletín Oficial, bans the use, sale, advertising and distribution across Argentina, including online, of human-use products that list retatrutide as an ingredient.
What it means: Retatrutide products are banned in Argentina until ANMAT authorises one. We couldn't open the Boletín Oficial text, so this row rests on the news report.
After a consumer had uncontrollable vomiting, a torn oesophagus and hospital treatment, the TGA tested the unmarked vial sold as retatrutide: it held undeclared semaglutide and no retatrutide, at about 8 times the semaglutide level in approved products.
What it means: You can't tell from the vial what's inside. This one held a different drug at a much higher strength than any approved product.
FDA warned 5 more online peptide sellers, in Arizona, Florida, North Carolina and Texas, that their retatrutide products (listed as "GLP-3R", "GLP-3 RT" and "GLP-3 Reta") are unapproved new drugs.
What it means: The latest batch we found. FDA's warning-letter database lists 21 letters that mention retatrutide, from December 2024 to August 2026.
The TGA and NSW Police seized more than $120,000 (Australian) of illicit peptide and steroid products, including retatrutide, from 2 homes allegedly linked to a social media influencer the TGA had warned before.
What it means: In Australia, promoting unapproved peptides on social media is treated as unlawful advertising, and the stock can be seized.
Lilly Canada's public safety notice said retatrutide "has not yet been approved for human use by Health Canada or any other regulatory agency in the world" and cannot be lawfully sold to consumers.
What it means: Lilly asks Canadians to report suspected products to Health Canada, local police or its Customer Response Centre at 1-888-545-5972.
Lilly filed 6 lawsuits against US sellers: Aesthetic Envy (N.D. Cal.), Astra Peptides (W.D. Tex.), Legendary Peptides (E.D. Tex.), Striker Pharmacy (S.D. Tex.), Texas Peptides (W.D. Tex.) and Lone Star Peptide Co. (S.D. Tex.). It said it had referred more than 200 people and businesses to regulators and law enforcement.
What it means: These are civil suits by Lilly, not criminal charges. We haven't found court records showing how any of them ended.
MHRA's summer warning said retatrutide is not authorised in the UK, so anyone selling it is doing so illegally, and that there's no guarantee these products even contain retatrutide.
What it means: In the UK, side effects from any medicine can be reported to MHRA's Yellow Card scheme.
Victoria's Chief Health Officer reported 6 cases of acute liver injury since January 2026 in people who used unapproved products labelled Retatrutide, possibly from a contaminant. The alert was still active and unchanged when we checked.
What it means: Signs to act on: tiredness, yellow skin or eyes, belly pain, dark urine and unusual bruising. In Victoria the Poisons Information Centre is on 13 11 26.
The TGA and Australia's Chief Medical Officer warned about unapproved peptides, naming retatrutide, and listed reported harms including liver damage and severe allergic reactions needing hospital care.
What it means: A national warning, issued the same day as Victoria's liver alert.
MHRA agreed Lilly's paediatric investigation plan for retatrutide in obesity (MHRA-102112-PIP01-25), with a deferral and a waiver for children from birth to under 6.
What it means: A step toward a future UK filing. It is not a marketing authorisation; retatrutide is not authorised in the UK.
Two men were arrested after MHRA's largest-ever seizure of unlicensed weight loss medicines: about 12,000 doses at a country estate near Northampton believed to make retatrutide and tirzepatide products.
What it means: The two were arrested on suspicion of offences under the Human Medicines Regulations 2012; MHRA said enquiries were ongoing.
Medsafe's consumer advisory on unapproved peptides named retatrutide and said any retatrutide sold to the public comes from the black market.
What it means: If you've injected one and feel unwell, Medsafe says get medical advice straight away and report the reaction to its adverse-reaction database.
Health Canada advisory RA-81874 listed retatrutide among unauthorized injectable peptide drugs it has seized, and said it is working with the Canada Border Services Agency to stop shipments.
What it means: Retatrutide can't be sold legally in Canada. Report side effects through MedEffect Canada and complaints about a product to Health Canada.
FDA warned 4 online peptide sellers in California, Arizona, Colorado and Florida that their retatrutide products, sold under names like "GLP-3 RT" and "GLP-1-R", are unapproved new drugs.
What it means: Code names don't change anything. FDA cited the sellers' own weight-loss claims and dosing charts as evidence the vials were meant for people.
MHRA searched a farm near Sleaford and a home in Grantham and seized almost 2,000 doses of unauthorised weight loss medicines awaiting dispatch. The sites were believed to make products including retatrutide and tirzepatide.
What it means: UK supply of "retatrutide" runs through unlicensed workshops like these, with no checks on what goes in the pen.
FDA's letter to GenoGenix, an outsourcing facility in Boca Raton, Florida, listed repackaged retatrutide among drugs with no approved application, alongside sterility failures and subpotent products.
What it means: Even a registered outsourcing facility can't legally repackage retatrutide. The same letter shows what weak sterile practice can look like.
FDA warned Darmerica, an ingredient (API) distributor in Davie, Florida, for supplying retatrutide to pharmacies that compound under section 503A, though retatrutide is not eligible for compounding.
What it means: FDA is going after the ingredient suppliers behind compounded retatrutide as well as the shops that sell it.
MHRA officers, with Northamptonshire Police, raided a warehouse near Northampton and seized more than 2,000 unlicensed retatrutide and tirzepatide pens awaiting dispatch, plus tens of thousands of empty pens.
What it means: MHRA says retatrutide is not approved for UK use, and products sold in the UK claiming to contain it are likely illegal.
The court split the case. It upheld FDA's refusal to call retatrutide a protein, but found FDA's reasons on the "analogous products" question arbitrary and capricious, vacated that part and sent it back to FDA.
What it means: Neither side won outright. FDA had to look again at one question, and it answered it on Oct 2, 2026.
FDA sent warning letters to 6 telehealth and online sellers, one of them based in Germany, saying their compounded retatrutide products were unapproved and misbranded drugs.
What it means: A telehealth storefront or a doctor's name on the site doesn't make retatrutide legal to sell in the US.
FDA told the Federation of State Medical Boards that compounded retatrutide does not qualify for the compounding exemptions in sections 503A or 503B, and recommended that consumers not buy retatrutide sold with disclaimer labels.
What it means: No legal compounded retatrutide exists in the US. A clinic or pharmacy offering it is outside the compounding rules.
FDA sent warning letters to 4 online peptide sellers (in California, New York, Alabama and Wyoming) whose retatrutide products it called unapproved new drugs. FDA posted them on Dec 17, 2024.
What it means: The first FDA letters to name retatrutide. FDA judged the vials by the sellers' own weight-loss claims, whatever the label said.
EMA agreed Lilly's paediatric investigation plan for retatrutide (decision P/0336/2024, EMEA-003258-PIP02-23), with a deferral and a waiver.
What it means: An agreed plan for future studies in children, a step EU rules require before a filing. It is not a marketing authorisation; nothing is approved in the EU.
FDA answered Lilly's request for designation: retatrutide is a drug, not a biological product, because it is neither a "protein" nor an "analogous product" to one.
What it means: This decides the filing route (a new drug application rather than a biologics license application). It says nothing about whether retatrutide will be approved.
FDA has sent 21 warning letters that mention retatrutide since December 2024, every one of them to a business selling or supplying an unapproved product, because no approved version of retatrutide exists anywhere. The log above puts those letters next to every other regulator action, court filing, harm report and lab test we could check against its source, newest first, with the date we last checked it. If you're trying to work out whether retatrutide is legal where you live, start with is retatrutide legal, then come back here for the record.
What's in the log
Each entry is one dated event, sorted into one of six types:
Warning: regulator alerts and advisories, including FDA warning letters, grouped by the day FDA sent them.
Enforcement: raids, seizures and arrests.
Lawsuit: court filings, both Lilly's suits against sellers and Lilly's own case against the FDA.
Adverse event: reports of harm in people who used products sold as retatrutide.
Lab test: what turned up when someone tested a vial.
Regulatory decision: rulings on how retatrutide is classified or filed, and formal plans agreed with regulators.
As of November 1, 2026, the log covers the United States, the United Kingdom, Australia, Canada, the European Union, New Zealand, Singapore and Argentina. Use the filters to narrow it by type or region. Each entry's source link opens the original document, and warning-letter entries list every letter in the batch.
How we check each entry
An entry goes in only after we've opened the primary document: the regulator's own page, the court filing, the FDA letter or Lilly's release. A few facts had no public primary document we could open, so for those we name the news outlet in the entry itself, as in "CBS News reported". Those entries are the FDA death reports, the US poison-center counts, the CBS lab test and Argentina's ban.
We left some things out. As of November 1, 2026 we couldn't confirm from court records the 5 lawsuits Lilly reportedly filed on October 8, 2026, or the reported settlements and dismissals of the August cases. We also couldn't open the record of the Florida criminal case that Lilly mentions without a name or date. Those stay off the log until a document turns up. Every date is the date of the event or of the document; the one exception is the Sport Integrity Australia page, which carries no date, so it sits at the date we could confirm it.
What the alerts have in common
The pattern repeats across countries. A product sold as retatrutide often isn't what the label says. The TGA's September 2026 test found no retatrutide at all, only semaglutide at about 8 times the level in approved products, in a vial that left a buyer in hospital with a torn oesophagus. Victoria's health department has 6 cases of acute liver injury it links, possibly through a contaminant, to products labelled Retatrutide. The MHRA has made 4 large seizures involving retatrutide products in a year, the latest of more than 12,000 fake pens in Birmingham.
The US numbers come mostly from news reports, and that's worth keeping in mind. CBS News reported that America's Poison Centers logged 862 retatrutide exposures in the three months to September 2026, up from 249 in the first quarter. An exposure is a call about contact with a product, not a confirmed poisoning. The 2 death reports to FDA that CBS described haven't been verified by FDA, and a report alone can't show cause. Our page on deaths linked to retatrutide goes through what's known and what isn't.
Our read: the regulators' warnings and the lab results point the same way. The risk with online retatrutide comes less from the molecule than from not knowing what's in the vial, and our guide to retatrutide testing covers what a lab report can and can't tell you about a vial.
The court case is a separate matter. Lilly's fight with FDA is over whether retatrutide gets filed as a drug or a biologic. FDA's answer, on October 2, 2026, is a drug, filed under section 505, and Lilly's appeal is pending. None of it makes online products legal. The background is on our page about whether retatrutide is a drug or a biologic.
How to report a problem with retatrutide
Get medical help now
Call 911 (or 000 in Australia) for trouble breathing, swelling of the face or throat, or vomiting you can't stop. See a doctor the same day for yellow skin or eyes, dark urine, belly pain or unusual bruising, the signs Victoria's health department lists for liver injury. Take the vial and its label with you.
Once you're safe, a report helps regulators spot a bad batch. Where to send it:
United States: FDA's MedWatch online form (accessdata.fda.gov/scripts/medwatch) for side effects, and Poison Help on 1-800-222-1222 for free, confidential advice at any hour.
Canada: Health Canada's MedEffect process for side effects, and its health product complaint process for the seller. Lilly Canada also takes reports on 1-888-545-5972.
United Kingdom: the MHRA Yellow Card scheme, which takes reports from anyone.
Australia: the TGA on 1800 020 653 or info@tga.gov.au. In Victoria, the Poisons Information Centre is on 13 11 26.
New Zealand: Medsafe's adverse reaction reporting form.
Singapore: HSA on 6866-3485 or hsa_is@hsa.gov.sg for suspicious sales.
Lilly also asks people in the US to report sellers to the Lilly Answers Center at 1-800-LillyRx. Keep the vial, the packaging, the seller's name and any batch number; regulators can test only what they can get.
Frequently asked questions
Has the FDA issued a warning about retatrutide?
Yes, many. FDA's warning letter database lists 21 letters that mention retatrutide, sent between December 2024 and August 2026 to online peptide sellers, telehealth sites, an ingredient distributor and an outsourcing facility. In a March 2025 letter to state medical boards, FDA also said compounded retatrutide doesn't qualify for the compounding exemptions and recommended that consumers not buy it.
Has retatrutide been recalled?
No approved retatrutide product exists, so there is nothing on the market to recall. What regulators have done instead is warn the public, block imports and seize stock: Health Canada, the TGA and the MHRA have all seized products sold as retatrutide.
Is fake retatrutide common?
Nobody has measured how common it is, but the tests we found are not reassuring. The TGA tested a vial sold as retatrutide in September 2026 and found no retatrutide, only undeclared semaglutide at about 8 times the level in approved products. In a CBS News test in October 2026, a vial bought at a bodega showed no peptide at all and grew 13 colonies of bacteria.
Has anyone died after using retatrutide bought online?
CBS News reported in October 2026 that FDA received 2 death reports after people used products sold as retatrutide, one in July and one in September 2026. FDA would not say whether it verified them, and a report to FDA doesn't show that the product caused the death.
Is retatrutide banned in sport?
Sport Integrity Australia says retatrutide is not on the 2026 Prohibited List. It warns that counterfeit retatrutide may be contaminated with banned substances, which could still lead to an anti-doping rule violation.
How do I report a bad reaction to retatrutide?
In the US, use FDA's MedWatch online form, and call Poison Help on 1-800-222-1222 for advice. In Canada, report through Health Canada's MedEffect process; in the UK, the MHRA Yellow Card scheme; in Australia, the TGA on 1800 020 653; in New Zealand, Medsafe's reporting form. If symptoms are severe, get emergency care first.
Sources
FDA warning letters: search results for retatrutide. U.S. Food and Drug Administration, 2026. fda.gov
FDA letter to the Federation of State Medical Boards on compounded retatrutide (Mar 31, 2025). U.S. Food and Drug Administration (posted by the Federation of State Medical Boards), 2025. fsmb.org
FDA letter to Eli Lilly on the issues remanded in Eli Lilly v. Kennedy (Oct 2, 2026). U.S. Food and Drug Administration (court filing via CourtListener), 2026. storage.courtlistener.com
Toxicity linked to unapproved peptide "Retatrutide". Department of Health, Victoria, 2026. health.vic.gov.au
Counterfeit weight loss pens worth £2 million seized by MHRA and West Midlands Police. Medicines and Healthcare products Regulatory Agency, 2026. gov.uk
Two deaths were reported to the FDA. Is the bootleg weight-loss drug "Reta" to blame?. CBS News, 2026. cbsnews.com
We bought and tested what was sold as an experimental weight loss drug. The lab results were "pretty terrifying.". CBS News, 2026. cbsnews.com
Think twice before injecting peptides bought online: unauthorized products can seriously harm you (RA-81874). Health Canada, 2026. recalls-rappels.canada.ca
Consumer advisory: unapproved peptide products health warning. Medsafe, 2026. medsafe.govt.nz
Risks of obtaining prescription medicines and unapproved injectable peptides through unauthorised channels. Health Sciences Authority, Singapore, 2026. hsa.gov.sg
Retatrutide (Reta) explained. Sport Integrity Australia, 2026. sportintegrity.gov.au
MedWatch: The FDA Safety Information and Adverse Event Reporting Program. U.S. Food and Drug Administration, 2026. fda.gov
Medical disclaimer. Retatrutide is an investigational medicine and no approved version exists yet. This page is educational, not medical advice. Talk to a doctor before starting, changing or stopping any medication, and get urgent care for severe symptoms.